Gritstone Oncology Inc. said FDA has granted Fast Track designation to GRANITE-001 for the treatment of colorectal cancer. GRANITE-001 is a personalized immunotherapy containing patient-specific neoantigens identified by Gritstone’s proprietary EDGETM artificial intelligence platform as the most relevant neoantigens to drive a tumor-specific T-cell attack.
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
